                         SEQUENCE LISTING

<110>  The Regents of the University of California
 
<120>  THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED 
       WITH ABNORMAL EXPRESSION OF CDKL5 GENE

<130>  00015-398WO1

<140>  Not yet assigned
<141>  2022-02-25

<150>  US 63/154,566
<151>  2021-02-26

<160>  13    

<170>  PatentIn version 3.5

<210>  1
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  EIF3C peptide

<400>  1

Gln Pro Leu Leu Leu Pro Ser Glu Asp Glu Glu Asp Thr Lys 
1               5                   10                  


<210>  2
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  RPTOR peptide

<400>  2

Gly Val His Ile His Gln Ala Gly Gly Pro Ser Pro Pro Ala Ser Ser 
1               5                   10                  15      


Thr Ser Ser Ser Ser Leu Thr Asn Asp Val Ala Lys 
            20                  25              


<210>  3
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  AKT1S1 peptide

<400>  3

Pro Ser Leu Pro Val Ser Val Pro Val Trp Gly Phe Lys 
1               5                   10              


<210>  4
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  AKT1S1 peptide

<400>  4

Arg Thr Glu Ala Arg Ser Pro Ser Asp Glu Glu Asn Gly Pro Pro Ser 
1               5                   10                  15      


Pro Ser Pro Asp Leu Asp Arg 
            20              


<210>  5
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LARP1 peptide

<400>  5

Asn Ala Leu Pro Pro Val Leu Thr Thr Val Asn Gly Gln Pro Ser Pro 
1               5                   10                  15      


Pro Glu His Ser Ala Pro Ala Lys 
            20                  


<210>  6
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPYSL2 peptide

<400>  6

Gly Leu Tyr Asp Gly Pro Val Cys Glu Val Ser Val Pro Thr Pro Lys 
1               5                   10                  15      


Pro Thr Val Thr Pro Ala Ser Ser Ala Lys 
            20                  25      


<210>  7
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPYSL3 peptide

<400>  7

Gly Met Tyr Asp Gly Pro Val Phe Asp Leu Thr Thr Thr Pro Lys Gly 
1               5                   10                  15      


Gly Pro Thr Pro Ala Gly Pro Ser Ala Arg Gly Ser Pro Thr Arg Pro 
            20                  25                  30          


Asn Pro Pro Val Arg 
        35          


<210>  8
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MAP1A peptide

<400>  8

Ser Leu Pro Ser Pro Glu Asp Ala Glu Ser Leu Ser Val Leu Ser Val 
1               5                   10                  15      


Pro Ser Pro Asp Thr Ala Asn Gln Glu Pro Thr Pro Lys 
            20                  25                  


<210>  9
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MAP1A peptide

<400>  9

Ser Glu Pro Gln Asp Phe Gln Glu Ala Asp Pro Ser Trp Gly Asp Thr 
1               5                   10                  15      


Lys 
    


<210>  10
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MAP1B peptide

<400>  10

Val Leu Ser Pro Leu Arg Ser Pro Pro Leu Ile Gly Ser Glu Pro Ser 
1               5                   10                  15      


Ala Pro Tyr Glu Ser Phe Leu Ser Ala Asp Asp Lys 
            20                  25              


<210>  11
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MAP1B peptide

<400>  11

Thr Thr Arg Pro Thr Pro Glu Glu Gly Gly Tyr Ser Tyr Asp Ile Ser 
1               5                   10                  15      


Glu Lys Thr Thr Pro Ser Pro Pro Glu Val Ser Gly Tyr Ser Tyr Glu 
            20                  25                  30          


Lys 
    


<210>  12
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MAP2 peptide

<400>  12

Val Asp His Gly Ala Glu Ile Ile Thr Gln Pro Ser Pro Gly Arg Ser 
1               5                   10                  15      


Pro Ser Val Ala Pro Ser Pro Arg 
            20                  


<210>  13
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MAP2 peptide

<400>  13

Ala Gly Lys Ser Gly Thr Ser Thr Pro Pro Thr Thr Pro Gly Ser Thr 
1               5                   10                  15      


Ala Ile Thr Pro Gly Pro Thr Pro Pro Ser Tyr Ser Ser Arg 
            20                  25                  30  


